Regeneron Pharmaceuticals reports $14.34 billion revenue for fiscal year ended December 31, 2025, up 1%

ยท REGN

Regeneron Pharmaceuticals reported revenue of $14.34 billion for the year ended December 31, 2025, an increase of 1% from the previous year ($14.2 billion).

For the same period it posted net income of $4.5 billion, up 2.1%, or $41.48 per diluted share (38.34 a year earlier).

That is a net margin of 31.4%.

On Sanad's AAOIFI Standard 21 screen, Regeneron Pharmaceuticals is currently questionable: interest-bearing debt is 2.7% of market capitalisation (limit 30%), and impure income is 4.4% of revenue (limit 5%).

Source: 10-K filed with the U.S. Securities and Exchange Commission on February 4, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.

More Regeneron Pharmaceuticals news